Biological and Medicinal Chemistry

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)



Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. To better understand lazertinib inhibition at the molecular level, we determined crystal structures of lazertinib in complex with both WT and mutant EGFR and compared its binding mode to that of structurally-related EGFR TKIs. We observe that lazertinib binds with the novel pyrazole moiety involved in hydrogen bonds and van der Waals interactions consistent with drug potency and T790M mutant selectivity. Biochemical assays and cell studies confirm that lazertinib effectively targets EGFR(L858R/T790M) and to a lesser extent against HER2 as consistent with an improved toxicity profile. The molecular basis for lazertinib inhibition of EGFR reported here highlights new strategies for structure-guided design of tyrosine kinase inhibitors.

Version notes

Altered Eck's author affiliation typo


Thumbnail image of Lazertinib_Manuscript_ChemRxiv.pdf

Supplementary material

Thumbnail image of Lazertinib_SI_Chemrxiv.pdf
Supplementary Information
Experimental methods, crystallographic data collection and refinement statistics, and supplemental images.